Advanced search
1 file | 987.00 KB Add to list

Pathophysiology of hypertension in the absence of nitric oxide/cyclic GMP signaling

Author
Abstract
The nitric oxide (NO)-cyclic guanosine monophosphate (cGMP) signaling system is a well-characterized modulator of cardiovascular function, in general, and blood pressure, in particular. The availability of mice mutant for key enzymes in the NO-cGMP signaling system facilitated the identification of interactions with other blood pressure modifying pathways (e.g. the renin-angiotensin-aldosterone system) and of gender-specific effects of impaired NO-cGMP signaling. In addition, recent genome-wide association studies identified blood pressure-modifying genetic variants in genes that modulate NO and cGMP levels. Together, these findings have advanced our understanding of how NO-cGMP signaling regulates blood pressure. In this review, we will summarize the results obtained in mice with disrupted NO-cGMP signaling and highlight the relevance of this pathway as a potential therapeutic target for the treatment of hypertension.
Keywords
SOLUBLE GUANYLATE-CYCLASE, DEPENDENT PROTEIN-KINASE, VASCULAR, SMOOTH-MUSCLE, ENDOTHELIAL NO SYNTHASE, CARDIOMYOCYTE-SPECIFIC, OVEREXPRESSION, SYSTEMIC VASODILATOR RESPONSES, S-NITROSOGLUTATHIONE, REDUCTASE, GENOME-WIDE ASSOCIATION, CINACIGUAT BAY 58-2667, DOUBLE-KNOCKOUT MICE, Cyclic guanosine monophosphate, Blood pressure, Hypertension, Cardiovascular function, Soluble guanylate cyclase, Nitric oxide, Mutant, mice, Genetic variants, Renin-angiotensin-aldosterone signaling, Gender, S-nitrosylation, Therapeutics

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 987.00 KB

Citation

Please use this url to cite or link to this publication:

MLA
Thoonen, Robrecht et al. “Pathophysiology of Hypertension in the Absence of Nitric Oxide/cyclic GMP Signaling.” CURRENT HYPERTENSION REPORTS 15.1 (2013): 47–58. Print.
APA
Thoonen, R., Sips, P., Bloch, K. D., & Buys, E. S. (2013). Pathophysiology of hypertension in the absence of nitric oxide/cyclic GMP signaling. CURRENT HYPERTENSION REPORTS, 15(1), 47–58.
Chicago author-date
Thoonen, Robrecht, Patrick Sips, Kenneth D Bloch, and Emmanuel S. Buys. 2013. “Pathophysiology of Hypertension in the Absence of Nitric Oxide/cyclic GMP Signaling.” Current Hypertension Reports 15 (1): 47–58.
Chicago author-date (all authors)
Thoonen, Robrecht, Patrick Sips, Kenneth D Bloch, and Emmanuel S. Buys. 2013. “Pathophysiology of Hypertension in the Absence of Nitric Oxide/cyclic GMP Signaling.” Current Hypertension Reports 15 (1): 47–58.
Vancouver
1.
Thoonen R, Sips P, Bloch KD, Buys ES. Pathophysiology of hypertension in the absence of nitric oxide/cyclic GMP signaling. CURRENT HYPERTENSION REPORTS. 2013;15(1):47–58.
IEEE
[1]
R. Thoonen, P. Sips, K. D. Bloch, and E. S. Buys, “Pathophysiology of hypertension in the absence of nitric oxide/cyclic GMP signaling,” CURRENT HYPERTENSION REPORTS, vol. 15, no. 1, pp. 47–58, 2013.
@article{8507158,
  abstract     = {The nitric oxide (NO)-cyclic guanosine monophosphate (cGMP) signaling system is a well-characterized modulator of cardiovascular function, in general, and blood pressure, in particular. The availability of mice mutant for key enzymes in the NO-cGMP signaling system facilitated the identification of interactions with other blood pressure modifying pathways (e.g. the renin-angiotensin-aldosterone system) and of gender-specific effects of impaired NO-cGMP signaling. In addition, recent genome-wide association studies identified blood pressure-modifying genetic variants in genes that modulate NO and cGMP levels. Together, these findings have advanced our understanding of how NO-cGMP signaling regulates blood pressure. In this review, we will summarize the results obtained in mice with disrupted NO-cGMP signaling and highlight the relevance of this pathway as a potential therapeutic target for the treatment of hypertension.},
  author       = {Thoonen, Robrecht and Sips, Patrick and Bloch, Kenneth D and Buys, Emmanuel S.},
  issn         = {1522-6417},
  journal      = {CURRENT HYPERTENSION REPORTS},
  keywords     = {SOLUBLE GUANYLATE-CYCLASE,DEPENDENT PROTEIN-KINASE,VASCULAR,SMOOTH-MUSCLE,ENDOTHELIAL NO SYNTHASE,CARDIOMYOCYTE-SPECIFIC,OVEREXPRESSION,SYSTEMIC VASODILATOR RESPONSES,S-NITROSOGLUTATHIONE,REDUCTASE,GENOME-WIDE ASSOCIATION,CINACIGUAT BAY 58-2667,DOUBLE-KNOCKOUT MICE,Cyclic guanosine monophosphate,Blood pressure,Hypertension,Cardiovascular function,Soluble guanylate cyclase,Nitric oxide,Mutant,mice,Genetic variants,Renin-angiotensin-aldosterone signaling,Gender,S-nitrosylation,Therapeutics},
  language     = {eng},
  number       = {1},
  pages        = {47--58},
  title        = {Pathophysiology of hypertension in the absence of nitric oxide/cyclic GMP signaling},
  url          = {http://dx.doi.org/10.1007/s11906-012-0320-5},
  volume       = {15},
  year         = {2013},
}

Altmetric
View in Altmetric
Web of Science
Times cited: